Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response.

Yin X, Luistro L, Zhong H, Smith M, Nevins T, Schostack K, Hilton H, Lin TA, Truitt T, Biondi D, Wang X, Packman K, Rosinski J, Berkofsky-Fessler W, Tang JP, Pant S, Geho D, Vega-Harring S, Demario M, Levitsky H, Simcox M.

Clin Cancer Res. 2013 Oct 15;19(20):5686-98. doi: 10.1158/1078-0432.CCR-13-0405. Epub 2013 Aug 23.

2.

Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms.

Rice KL, Lin X, Wolniak K, Ebert BL, Berkofsky-Fessler W, Buzzai M, Sun Y, Xi C, Elkin P, Levine R, Golub T, Gilliland DG, Crispino JD, Licht JD, Zhang W.

Blood Cancer J. 2011 Nov;1(11):e40. doi: 10.1038/bcj.2011.39. Epub 2011 Nov 11.

3.

Serum cardiac troponin I concentrations transiently increase in rats given rosiglitazone.

Mikaelian I, Buness A, Hirkaler G, Fernandes R, Coluccio D, Geng W, Visalli T, Bachynsky MO, Berkofsky-Fessler W, Kanwal C, Hilton H, Nicklaus R, Hoflack JC, Dunn M, Sanders M, Giron M, Boyle BW, Singer T, Dick LS.

Toxicol Lett. 2011 Mar 5;201(2):110-5. doi: 10.1016/j.toxlet.2010.12.012. Epub 2010 Dec 21.

PMID:
21172411
4.

Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F.

Berkofsky-Fessler W, Buzzai M, Kim MK, Fruchtman S, Najfeld V, Min DJ, Costa FF, Bischof JM, Soares MB, McConnell MJ, Zhang W, Levine R, Gilliland DG, Calogero R, Licht JD.

Clin Cancer Res. 2010 Sep 1;16(17):4339-52. doi: 10.1158/1078-0432.CCR-10-1092. Epub 2010 Jul 2.

5.

Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties.

Luistro L, He W, Smith M, Packman K, Vilenchik M, Carvajal D, Roberts J, Cai J, Berkofsky-Fessler W, Hilton H, Linn M, Flohr A, Jakob-Røtne R, Jacobsen H, Glenn K, Heimbrook D, Boylan JF.

Cancer Res. 2009 Oct 1;69(19):7672-80. doi: 10.1158/0008-5472.CAN-09-1843. Epub 2009 Sep 22. Erratum in: Cancer Res. 2012 Apr 15;72(8):2151.

6.

Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients.

Berkofsky-Fessler W, Nguyen TQ, Delmar P, Molnos J, Kanwal C, DePinto W, Rosinski J, McLoughlin P, Ritland S, DeMario M, Tobon K, Reidhaar-Olson JF, Rueger R, Hilton H.

Mol Cancer Ther. 2009 Sep;8(9):2517-25. doi: 10.1158/1535-7163.MCT-09-0083. Epub 2009 Sep 15.

7.

Promyelocytic leukemia zinc finger protein regulates interferon-mediated innate immunity.

Xu D, Holko M, Sadler AJ, Scott B, Higashiyama S, Berkofsky-Fessler W, McConnell MJ, Pandolfi PP, Licht JD, Williams BR.

Immunity. 2009 Jun 19;30(6):802-16. doi: 10.1016/j.immuni.2009.04.013. Epub 2009 Jun 11.

8.

WT1 induction of mitogen-activated protein kinase phosphatase 3 represents a novel mechanism of growth suppression.

Morrison DJ, Kim MK, Berkofsky-Fessler W, Licht JD.

Mol Cancer Res. 2008 Jul;6(7):1225-31. doi: 10.1158/1541-7786.MCR-08-0078.

9.

A pathologic link between Wilms tumor suppressor gene, WT1, and IFI16.

Kim MK, Mason JM, Li CM, Berkofsky-Fessler W, Jiang L, Choubey D, Grundy PE, Tycko B, Licht JD.

Neoplasia. 2008 Jan;10(1):69-78.

10.

Growth suppression by acute promyelocytic leukemia-associated protein PLZF is mediated by repression of c-myc expression.

McConnell MJ, Chevallier N, Berkofsky-Fessler W, Giltnane JM, Malani RB, Staudt LM, Licht JD.

Mol Cell Biol. 2003 Dec;23(24):9375-88.

11.

Identification of a neocentromere in a rearranged Y chromosome with no detectable DYZ3 centromeric sequence.

Assumpção JG, Berkofsky-Fessler W, Viguetti Campos N, Trevas Maciel-Guerra A, Li S, Melaragno MI, Palandi de Mello M, Warburton PE.

Am J Med Genet. 2002 Dec 1;113(3):263-7.

PMID:
12439894

Supplemental Content

Loading ...
Support Center